Newron Pharmaceuticals Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '25 Dec 2, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Market Capitalization	390	186	95	28	28	35	Upgrade
Market Cap Growth	167.22%	95.60%	239.07%	0.38%	-21.34%	-66.00%	Upgrade
Enterprise Value	399	223	126	44	33	22	Upgrade
Last Close Price	19.40	9.29	5.60	1.47	1.50	1.91	Upgrade
PE Ratio	15.38	11.72	-	-	-	-	Upgrade
PS Ratio	6.50	3.61	10.48	4.59	4.84	6.74	Upgrade
PB Ratio	246.21	127.32	-3.17	-1.99	8.98	2.06	Upgrade
P/TBV Ratio	246.37	127.32	-	-	8.98	2.06	Upgrade
EV/Sales Ratio	6.68	4.34	13.95	7.26	5.77	4.13	Upgrade
EV/EBITDA Ratio	11.31	8.52	-	-	-	-	Upgrade
EV/EBIT Ratio	11.36	8.53	-	-	-	-	Upgrade
Debt / Equity Ratio	33.23	34.62	-1.62	-3.25	13.87	1.53	Upgrade
Debt / EBITDA Ratio	1.49	1.91	-	-	-	-	Upgrade
Asset Turnover	1.39	1.15	0.29	0.14	0.11	0.09	Upgrade
Quick Ratio	1.40	2.42	0.62	5.50	10.58	5.50	Upgrade
Current Ratio	1.51	2.60	0.68	5.65	10.79	5.50	Upgrade
Return on Equity (ROE)	-	-	-	-	-146.43%	-77.71%	Upgrade
Return on Assets (ROA)	50.97%	36.44%	-23.05%	-18.96%	-15.19%	-20.26%	Upgrade
Return on Capital (ROIC)	60.97%	46.45%	-28.99%	-21.37%	-17.21%	-23.21%	Upgrade
Return on Capital Employed (ROCE)	165.20%	64.80%	380.00%	-41.40%	-26.40%	-40.80%	Upgrade
Earnings Yield	6.50%	8.54%	-17.09%	-62.50%	-53.44%	-59.23%	Upgrade
FCF Yield	6.30%	-9.50%	-10.70%	-39.69%	-41.12%	-44.07%	Upgrade
Buyback Yield / Dilution	-16.86%	-15.30%	-	-	-	-	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.